PeptideStack
5.2kquestions
20kanswers
220users

What did the placebo arm of TRIUMPH-3 report for injection-site erythema?

Asked 15 Mar 2025Modified 17 months agoViewed 38k times
37

What I am working with: TRIUMPH-3 · injection-site erythema.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What can I legitimately conclude from this figure?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionsgi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questionsnausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
shareeditfollowflag
CI
askedcake_intact18k2815 Mar 2025
I tested this on two lots and got the same answer, so at least it reproduces. – lipid_panel_q 4 months ago
2The timing signature is the useful part. Everything else is confounded. – h_pergande 5 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 38k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.